Practice

Approval Process for Biosimilars

June 17th 2017

Differences Between Biosimilars and Generic Drugs

June 17th 2017

Knowledge Gaps With Biosimilars

June 17th 2017

Dr Joseph Fuhr: Interchangeability Poses Too Much Risk, Too Little Reward

June 8th 2017

Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, discusses interchangability in biosimilars.

Demand for Greater Transparency, More Data in Demonstrating Biosimilars' Interchangeability

June 6th 2017

By Kelly Davio

The Biologics Prescribers Collaborative (BPC), an organization comprising 6 member groups whose memberships prescribe biologic agents, has released its comment letter to the FDA on the agency’s Considerations in Demonstrating Interchangeability With a Reference Product draft guidance, calling on the FDA to do more to “promote transparency and patient safety."

Biosimilars May Play an Important Role in Achieving ACA Reform Goals, but Challenges Remain

June 6th 2017

By Kelly Davio

In a new paper published in Cancer Care Management and Research, researchers examine the progress that the United States has made toward reforming healthcare since the passage of the Affordable Care Act (ACA) in 2010, with a particular focus on the role that biosimilar products may play in achieving the ACA’s 3-fold goal of increasing access to treatment, controlling costs, and improving patient care.

Study Underscores Need for Educating Community Oncologists on Biosimilars

June 2nd 2017

By Kelly Davio

Research presented at the 22nd Annual International Meeting of The International Society for Pharmacoeconomics and Outcomes Research demonstrates gaps in physicians’ education on biosimilar agents.

Analysis of Physicians' Notes Shows Slow Uptake for Filgrastim-sndz

June 1st 2017

By Kelly Davio

In a study presented at the 22nd Annual International Meeting of The International Society for Pharmacoeconomics and Outcomes Research, researchers sought to identify physicians’ documented granulocyte colony-stimulating factor (G-CSF) use, with a particular focus on filgrastim-sndz since its entry into the marketplace, and identified a slow US uptake for the biosimilar.

Formulary Management an Important Consideration for Biosimilar Stakeholders

June 1st 2017

By Molly Billstein Leber, PharmD, BCPS, FASHP

Comments on the FDA's Biosimilar Interchangeability Draft Guidance Highlight a Growing Need for Clarity

May 30th 2017

By Jackie Syrop